Organization · Venture Capital
SymBiosis
SymBiosis Capital Management is a biotechnology venture capital firm based in Bentonville, Arkansas, focused on investing in biotherapeutics innovations for serious diseases. They target companies developing advanced therapeutic platforms that are nearing human trials.
Overview
What SymBiosis does
What SymBiosis is
SymBiosis Capital Management is a biotechnology venture capital firm based in Bentonville, Arkansas, focused on investing in biotherapeutics innovations for serious diseases. They target companies developing advanced therapeutic platforms that are nearing human trials.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2019
- Approximate age
- About 7 years
- Structured capabilities
- Funder
- Last reviewed
- April 9, 2026
Official channels
Find SymBiosis elsewhere
Open the official website or a supported primary organization account.
Capability profile
SymBiosis as a funder
Investment thesis
SymBiosis Capital Management focuses on investing in bioengineering innovations that target life-threatening diseases through advanced therapeutic platforms.
Focus narrative
SymBiosis invests in biotechnology companies across various modalities, including biologics, cell therapy, genetic medicine, and small molecules. They target companies that have lead candidates reaching human proof-of-concept or are expected to do so with their initial investment round, focusing on late pre-clinical through clinical stages.
Value beyond capital
SymBiosis adds value to its portfolio companies by providing access to a network of industry experts and resources, facilitating faster market entry for biotherapeutics through initiatives like the BioAR Trial Accelerator, and supporting companies in navigating the complexities of clinical trials and regulatory approvals.
Terms and economics
- Typical check
- $5,000,000–$15,000,000
- Sweet spot
- $10,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A
- Regions
- Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 20
Portfolio context
Notable portfolio companies include: Aardvark Therapeutics: Focuses on metabolic disease treatments. AdvanCell: Works on scalable targeted alpha therapy for cancer. Aeovian Pharmaceuticals: Develops small-molecule therapies for TSC epilepsy. Attivare Therapeutics: Offers a modular vaccine platform based on immuno-material technology. Clene Nanomedicine: Specializes in nanotherapeutics for neurodegenerative diseases. eGenesis: Aims to address the transplant shortage with human-compatible xenotransplants. Evommune: Engages in novel immunology research through skin. Paradox Immunotherapeutics: Develops targeted therapies for protein misfolding diseases. Tenaya Therapeutics: Focuses on curative gene therapies for rare heart diseases.
Common questions
What to know about SymBiosis
Upseed classifies SymBiosis under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 9, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.